Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW766944 · 1 trial · 1 indication
Sputum was collected according to the Hargreave/Nair Sputum Induction procedures.Each site performed their sputum analysis locally. Sputum induction for eosinophils was carried out at screening and Day 10. The absolute cell count of eosinophils in induced sputum has been presented.
Sputum was collected according to the Hargreave/Nair Sputum Induction procedures. Each site performed their sputum analysis locally. At Visit 5 (Day 17), all participants were given 30 mg oral daily prednisone for 5 days and participants returned to clinic at a Post Oral Prednisone Visit (Visit 6) at Day 22. Sputum induction for eosinophils was carried out at screening and Post Oral Prednisone Visit (Day 22). The absolute cell count of eosinophils in induced sputum has been presented.
Sputum was collected according to the Hargreave/Nair Sputum Induction procedures. Each site performed their sputum analysis locally. Sputum induction for eosinophils was carried out at screening and Day 10. Percentage count of eosinophils in induced sputum has been presented.
Sputum was collected according to the Hargreave/Nair Sputum Induction procedures. Each site performed their sputum analysis locally. At Visit 5, all participants were given 30 mg oral daily prednisone for 5 days and participants returned to clinic at a Post Oral Prednisone Visit (Visit 6) at Day 22. Sputum induction for eosinophils was carried out at screening and Post Oral Prednisone Visit (Day 22). Percentage count of eosinophils in induced sputum has been presented.
| Arm | Type | Description |
|---|---|---|
| GW766944 | ACTIVE_COMPARATOR | This is the active drug (GW766944) |
| Placebo | PLACEBO_COMPARATOR | Placebo Arm. |
| Name | Type | Description |
|---|---|---|
| GW766944 | DRUG | Drug: GW766944 (Active Drug Treatment) |
| Placebo | OTHER | This is placebo to match. |
Inclusion Criteria: * Physician diagnosis of asthma (\>12% improvement in FEV1 with a bronchodilator or PC20 methacholine less than 8 mg/ml) documented within the past 2 years. * Males and females aged ≥18-75 years inclusive. * A female subject is eligible to participate if she is of: * Non-childbe...
GW766944 is an investigational small molecule being studied for the treatment of asthma. It is administered orally and has been evaluated in a Phase 2 clinical trial. The drug is not approved and remains in clinical development for this respiratory condition.
GW766944 is an oral CCR3 antagonist. It targets the CCR3 receptor, which is involved in the recruitment of eosinophils and other inflammatory cells implicated in asthma. By blocking this receptor, the drug aims to reduce airway inflammation associated with the condition.
GW766944 is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. The company has conducted clinical research on this investigational drug for the treatment of asthma.
GW766944 is in Phase 2 of clinical development. It has completed a Phase 2 trial, and it remains an investigational drug. It has not received regulatory approval and is not yet available for commercial use.
GW766944 has been studied in one completed Phase 2 clinical trial with the identifier NCT01160224. This randomized, double-blind, placebo-controlled trial enrolled 60 participants with asthma in Canada. The trial was completed, and no active trials are currently listed for this drug.
Yes, GW766944 is an oral CCR3 antagonist. The clinical trial NCT01160224 is titled "Oral GW766944 (Oral CCR3 Antagonist)," confirming that GW766944 is the drug being evaluated as an oral CCR3 antagonist for the treatment of asthma.